NCT06647134View on ClinicalTrials.gov

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

RecruitingOBSERVATIONAL

Enrollment

20

Participants

Timeline

Start Date

September 11, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2028

Conditions

ArthritisPolymyalgia RheumaticaImmune Checkpoint Inhibitors

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER